Vertex Pharmaceuticals (VRTX) Cash from Operations (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Cash from Operations of 1428100000.0 for Q1 2026, up 74.39% year-over-year from 818900000.0 in Q1 2025, and up 186.77% quarter-over-quarter from 498000000.0 in Q4 2025.
Vertex Pharmaceuticals (VRTX) Cash from Operations (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Cash from Operations history runs 18 years deep, the most recent figure standing at 1428100000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 74.39% year-over-year to 1428100000.0; the TTM figure through Mar 2026 stood at 4240600000.0 (up 532.58% YoY), while the FY2025 annual figure was 3631400000.0, up 837.19% from the prior year.
- Cash from Operations for Q1 2026 stood at 1428100000.0, up from 498000000.0 in the prior quarter.
- The five-year high for Cash from Operations was 1428100000.0 in Q1 2026, with the low at 3753600000.0 in Q2 2024.
- The 5-year median for Cash from Operations is 1073100000.0 (2025), against an average of 719652941.18.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations surged 670.76% in 2022, then plunged 430.89% in 2024.
- Vertex Pharmaceuticals' Cash from Operations stood at 1078400000.0 in 2022, then sank by 78.25% to 234600000.0 in 2023, then soared by 149.19% to 584600000.0 in 2024, then retreated by 14.81% to 498000000.0 in 2025, then surged by 186.77% to 1428100000.0 in 2026.
- Business Quant data shows VRTX's Cash from Operations at 1428100000.0 in Q1 2026, 498000000.0 in Q4 2025, and 1241400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -270.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Bn |
| Jun 30, 2026 | 1.13 Bn |
| Mar 31, 2026 | 1.43 Bn |
| Mar 31, 2026 | 1.43 Bn |
| Dec 31, 2025 | 498.00 Mn |
| Dec 31, 2025 | 498.00 Mn |
| Sep 30, 2025 | 1.24 Bn |
| Sep 30, 2025 | 1.24 Bn |
| Jun 30, 2025 | 1.07 Bn |
| Jun 30, 2025 | 1.07 Bn |
| Mar 31, 2025 | 818.90 Mn |
| Mar 31, 2025 | 818.90 Mn |
| Dec 31, 2024 | 584.60 Mn |
| Dec 31, 2024 | 584.60 Mn |
| Sep 30, 2024 | 1.37 Bn |
| Sep 30, 2024 | 1.37 Bn |
| Jun 30, 2024 | -3.75 Bn |
| Jun 30, 2024 | -3.75 Bn |
| Mar 31, 2024 | 1.31 Bn |
| Mar 31, 2024 | 1.31 Bn |